Hepatitis B

Hepatitis B features

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Viral hepatitis in low and middle-income settings

  Management of HIV and hepatitis B or C co-infection in resource-limited settings....

  From:  HIV & AIDS treatment in practice

Hepatitis B news from aidsmap

• Just 18% of people with hepatitis/HIV co-infection and cirrhosis are screened for liver cancer as often as recommended

  There is a “strikingly low adherence” to clinical guidelines for ultrasound screening for hepatocellular carcinoma in western Europe, researchers report in the Journal of Viral Hepatitis.Over years or decades, chronic hepatitis B or C can cause serious liver disease ...

  10 June 2019 | Roger Pebody

• Higher HIV viral load and lower CD4 count linked to liver cancer risk

  People living with HIV who have a longer duration of detectable viral load and those with low CD4 cell counts have a higher likelihood of developing liver cancer in the absence of advanced fibrosis, according to a study presented ...

  13 March 2019 | Liz Highleyman

• Sixfold increased risk of infant HIV infection and high rates of low birth weight among women with HIV/hepatitis B co-infection

  Women with high levels of hepatitis B viraemia (>106IU/ml) who have co-infection with HIV had a more than sixfold increased risk of having infants with HIV infection compared to women with HIV alone or co-infected with low levels of ...

  12 March 2019 | Carole Leach-Lemens

• Nivolumab improves outcomes in liver cancer study

  Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the ...

  14 November 2017 | Liz Highleyman

• Daily aspirin therapy linked to lower liver cancer risk

  People with hepatitis B virus (HBV) who took an aspirin a day – often recommended to help prevent cardiovascular disease – had a lower risk of developing liver cancer, according to a study from Taiwan presented at the 2017 ...

  26 October 2017 | Liz Highleyman

• US FDA approves nivolumab immunotherapy for liver cancer

  The US Food and Drug Administration (FDA) last week granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumour activity, for people with hepatocellular carcinoma. Nivolumab, an antibody that blocks the PD-1 (programmed death ...

  28 September 2017 | Liz Highleyman

• Besifovir and tenofovir exalidex look promising as new hepatitis B drugs

  Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last month in Amsterdam. Besifovir is in phase 3 clinical ...

  08 May 2017 | Liz Highleyman

• EASL releases updated hepatitis B guidelines at International Liver Congress

  The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a special session at its International Liver Congress ...

  26 April 2017 | Liz Highleyman

• Switching to TAF for hepatitis B improves kidney function and bone loss

  People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the International Liver Congress last week in ...

  26 April 2017 | Liz Highleyman

• Tenofovir alafenamide approved for hepatitis B in Europe

  The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according to an announcement from Gilead Sciences. Tenofovir ...

  17 January 2017 | Liz Highleyman

More news

Hepatitis B news selected from other sources

• HIV-Related Factors Predict Reinforced Hepatitis B Vaccination Success

  Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination, according to an article published in Vaccine.

  03 June 2019 | Infectious Disease Advisor

• Summary from CROI 2019 for viral Hepatitis, from Jürgen Rockstroh

  Although no new drugs for HBV or HCV therapy were presented a whole range of important clinical studies were discussed which all have important clinical implications for daily practice.

  09 April 2019 | NATAP

• Demand for Hepatitis B Vaccines to Soar from End-use Industries and Push Revenues in the Global Market

  The global market for hepatitis B vaccine is growing at a significant rate due to increasing number of cases with hepatitis B infection. In addition, growing population and growing awareness for improved healthcare facilities is increasing the global market for hepatitis B vaccine.

  02 April 2019 | New Daily Herald

• Hepatitis B Virus Elevates Risk for Age-Related Macular Degeneration

  Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration (AMD), according to a new report. It’s possible that hepatitis B virus may even accelerate the progression of AMD.

  14 March 2019 | MD Magazine

• Undiagnosed HBV, HCV, HIV prevalent in newly diagnosed cancer cases

  Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

  18 January 2019 | Healio

• Advanced fibrosis found in one-third of patients with HIV/HBV coinfection

  Researchers observed significant fibrosis in more than one-third of patients with hepatitis B and HIV coinfection undergoing long-term combination antiretroviral therapy with viral suppression, according to a study published in American Journal of Gastroenterology.

  03 January 2019 | Healio

• Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

  The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

  15 October 2018 | Healio

• $20 blood test could help diagnose hepatitis B patients across Africa

  Researchers have developed an accurate diagnostic score that consists of inexpensive blood tests to identify patients who require immediate treatment against the deadly hepatitis B virus -- which can lead to liver damage or cancer.

  02 July 2018 | Science Daily

• 'Virus-cracking' molecules advance fight against hepatitis B

  Researchers have found that certain molecules -- currently under clinical trial -- are able to 'crack' the protective shell of the hepatitis B virus, suggesting it may be possible to attack the virus after it has already taken hold in the body.

  07 February 2018 | Science Daily

• Gilead's hepatitis B therapy to vie with 20 Korean therapies

  Korea has approved 20 products made by Korean companies targeting for No.1 chronic hepatitis B therapy Viread (compound: tenofovir disoproxil fumarate) made by Gilead.

  14 August 2017 | Korea Biomedical Review

More news